InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,041.20
(
0.45%
)
US TECH 100
17,003.60
(
0.85%
)
Dow Jones
38,040.24
(
0.36%
)
Brent Oil
83.64
(
0.11%
)
Bitcoin
58,391.38
(
0.26%
)
Post# of 251673
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 218534

Monday, 11/15/2021 11:39:37 AM

Monday, November 15, 2021 11:39:37 AM

Post# of 251673
BMY presents phase-2 Milvexian data at AHA:

https://www.businesswire.com/news/home/20211115005987/en

Milvexian is an oral anticoagulant that inhibits Factor XIa, a new MoA. Compared to FXa inhibitors such as Eliquis and Xarelto, Milvexian may be able to offer comparable efficacy with less bleeding risk.

BMY is developing Milvexian with JNJ, pursuant to a 2018 collaboration (#msg-140083631). BMY hopes Milvexian can replace some or all of the revenue from Eliquis, which loses exclusivity in 2028. Phase-3 trials for Milvexian are slated to start in 2022.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up